NOVATO, Calif., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced three abstracts related to UX007, a substrate replacement therapy intended for the treatment of fatty acid oxidation disorder (FAOD), and UX003, an enzyme replacement therapy intended for the treatment of mucopolysaccharidosis type 7 (MPS 7, Sly syndrome). The abstracts will be presented at the 12th International Congress of Inborn Errors of Metabolism on September 3-6, 2013 in Barcelona, Spain.
Help employers find you! Check out all the jobs and post your resume.
